We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.68%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$223M
AUM Growth
-$41.4M
(-16%)
Cap. Flow
-$38.1M
Cap. Flow
% of AUM
-17.06%
Top 10 Holdings %
Top 10 Hldgs %
11%
Holding
420
New
44
Increased
50
Reduced
231
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Mosaic Company
MOS
|
+$2.06M |
| 2 |
Petrobras
PBR
|
+$2M |
| 3 |
Vale
VALE
|
+$1.96M |
| 4 |
Cheniere Energy
CQP
|
+$1.94M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boise Cascade
BCC
|
+$2.62M |
| 2 |
Extra Space Storage
EXR
|
+$2.49M |
| 3 |
Canadian Natural Resources
CNQ
|
+$2.46M |
| 4 |
Imperial Oil
IMO
|
+$2.45M |
| 5 |
Avient
AVNT
|
+$2.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 20.16% |
| 2 | Real Estate | 20.02% |
| 3 | Healthcare | 16.51% |
| 4 | Energy | 10.55% |
| 5 | Utilities | 10.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
C4 Therapeutics
CCCC
$389M
| $128K | 0.06% |
5,275
-314
| -6% | -$7.63K |
|
|
VXRT
252
DELISTED
Vaxart
VXRT
| $128K | 0.06% |
25,383
-1,500
| -6% | -$7.6K |
|
|
AFMD
253
DELISTED
Affimed
AFMD
| $126K | 0.06% |
2,887
-172
| -6% | -$7.48K |
|
|
DVAX
254
DELISTED
Dynavax Technologies
DVAX
| $126K | 0.06% |
11,592
-685
| -6% | -$8.32K |
|
|
CNTA
255
DELISTED
Centessa Pharmaceuticals
CNTA
| $125K | 0.06% |
13,969
-829
| -6% | -$7.56K |
|
256
Arcus Biosciences
RCUS
$3.33B
| $125K | 0.06% |
3,954
-225
| -5% | -$7.54K |
|
257
AC Immune
ACIU
$231M
| $124K | 0.06% |
31,014
-1,838
| -6% | -$7.96K |
|
258
Protagonist Therapeutics
PTGX
$8.55B
| $124K | 0.06% |
5,216
-305
| -6% | -$8.59K |
|
|
AGEN
259
Agenus
AGEN
$276M
| $123K | 0.06% |
2,540
-151
| -6% | -$8.16K |
|
260
Kymera Therapeutics
KYMR
$8.66B
| $123K | 0.06% |
2,898
-173
| -6% | -$7.31K |
|
|
FLNA
261
Filana Therapeutics
FLNA
$42M
| $123K | 0.06% |
3,299
-200
| -6% | -$8.47K |
|
262
Xencor
XNCR
$1.45B
| $123K | 0.06% |
4,592
-277
| -6% | -$8.93K |
|
263
AnaptysBio
ANAB
$1.54B
| $122K | 0.05% |
4,949
-286
| -5% | -$8.66K |
|
264
Arcturus Therapeutics
ARCT
$165M
| $122K | 0.05% |
4,532
-271
| -6% | -$6.92K |
|
265
Compugen
CGEN
$212M
| $122K | 0.05% |
37,909
-2,252
| -6% | -$7.61K |
|
266
GH Research
GHRS
$1.92B
| $122K | 0.05% |
6,687
-399
| -6% | -$7.05K |
|
|
SGMO
267
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $122K | 0.05% |
20,983
-1,244
| -6% | -$7.4K |
|
|
DICE
268
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $121K | 0.05% |
6,316
-367
| -5% | -$6.55K |
|
269
Fate Therapeutics
FATE
$275M
| $120K | 0.05% |
3,091
-183
| -6% | -$7.09K |
|
|
CMRX
270
DELISTED
Chimerix, Inc.
CMRX
| $119K | 0.05% |
25,976
-1,538
| -6% | -$8.57K |
|
|
IMGN
271
DELISTED
Immunogen Inc
IMGN
| $118K | 0.05% |
24,846
-1,477
| -6% | -$8.18K |
|
272
Immunovant
IMVT
$7.93B
| $117K | 0.05% |
21,162
-1,273
| -6% | -$7.93K |
|
273
Phathom Pharmaceuticals
PHAT
$928M
| $117K | 0.05% |
8,575
-505
| -6% | -$8.16K |
|
274
4D Molecular Therapeutics
FDMT
$502M
| $116K | 0.05% |
7,683
-457
| -6% | -$7.18K |
|
275
Legend Biotech
LEGN
$3.65B
| $116K | 0.05% |
3,195
-189
| -6% | -$7.47K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, Virtus ETF Advisers held 420 positions worth $223M, down 16% from $265M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers withdrew a net $38.1M in Q1 2022, closing 47 positions and reducing 231 holdings. Its most notable exit was Boise Cascade, an estimated $2.62M position sold in full.
By sector, the portfolio is most concentrated in Materials at 20% of assets, up from 14% a quarter earlier, followed by Real Estate and Healthcare.
Against the trend, Virtus ETF Advisers opened a new position in The Mosaic Company worth $2.75M.
- Virtus ETF Advisers's largest Q1 2022 buy was The Mosaic Company: 41,283 shares worth $2.75M.
- Virtus ETF Advisers added most to Agnico Eagle Mines in Q1 2022, an estimated $1.28M increase.
- Virtus ETF Advisers's biggest Q1 2022 reduction was Gold Fields, cutting an estimated $1.09M.
- Virtus ETF Advisers fully exited Boise Cascade in Q1 2022, selling an estimated $2.62M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $223M portfolio in Q1 2022.
- Virtus ETF Advisers opened 44 new positions and closed 47 in Q1 2022.
- Virtus ETF Advisers's portfolio value fell 16% quarter-over-quarter to $223M.
Based on Virtus ETF Advisers's 13F filing for Q1 2022, filed 16 May 2022.